Simon Hawlina, Kosta Cerovic, Andraz Kondza, Peter Popovic, Jure Bizjak, Tomaz Smrkolj
{"title":"机器人辅助部分肾切除术中肿瘤破裂对中期肿瘤复发有影响吗?","authors":"Simon Hawlina, Kosta Cerovic, Andraz Kondza, Peter Popovic, Jure Bizjak, Tomaz Smrkolj","doi":"10.2478/raon-2023-0031","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Intraoperative kidney tumor rupture (TR) can occur during robot-assisted partial nephrectomy (RAPN) in daily clinical practice, but there are no solid guidelines on the management and implications of it. The purpose of the study was to investigate the impact of TR on tumor recurrences, what a surgeon should do if this adverse event occurs, and how to avoid it.</p><p><strong>Patients and methods: </strong>We retrospectively analyzed the first 100 patients who underwent RAPN at University Medical Centre Ljubljana, between 2018 and 2021. Patients were stratified into 2 groups (TR and no-TR) and were compared according to patient, tumor, pathologic, perioperative and postoperative characteristics and tumor recurrences, using the Mann-Whitney U test and chi-squared test.</p><p><strong>Results: </strong>Of the 100 patients, 14 had TR (14%); this occurred in tumors with higher RENAL nephrometry scores (P = 0.028) and mostly with papillary renal cell carcinomas (P = 0.043). Median warm ischemia time was longer for the TR group (22 <i>vs.</i> 15 min, <i>P</i> = 0.026). In terms of studied outcomes, there were no cases of local or distant recurrence after a median observation time of 39 months (interquartile range, 31-47 months) in both groups. We observed positive surgical margins on the final oncologic report in one case in the no-TR group.</p><p><strong>Conclusions: </strong>Tumor rupture during RAPN seems to be of no mid-term oncologic importance. According to presented results, we would recommend surgeons to proceed with tumor resection if this event occurs and abstain from conversion to radical nephrectomy or open partial nephrectomy. However, more similar cases should be studied to make more solid conclusions.</p>","PeriodicalId":21034,"journal":{"name":"Radiology and Oncology","volume":"57 3","pages":"348-355"},"PeriodicalIF":2.1000,"publicationDate":"2023-07-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10476903/pdf/","citationCount":"0","resultStr":"{\"title\":\"Does tumor rupture during robot-assisted partial nephrectomy have an impact on mid-term tumor recurrences?\",\"authors\":\"Simon Hawlina, Kosta Cerovic, Andraz Kondza, Peter Popovic, Jure Bizjak, Tomaz Smrkolj\",\"doi\":\"10.2478/raon-2023-0031\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Intraoperative kidney tumor rupture (TR) can occur during robot-assisted partial nephrectomy (RAPN) in daily clinical practice, but there are no solid guidelines on the management and implications of it. The purpose of the study was to investigate the impact of TR on tumor recurrences, what a surgeon should do if this adverse event occurs, and how to avoid it.</p><p><strong>Patients and methods: </strong>We retrospectively analyzed the first 100 patients who underwent RAPN at University Medical Centre Ljubljana, between 2018 and 2021. Patients were stratified into 2 groups (TR and no-TR) and were compared according to patient, tumor, pathologic, perioperative and postoperative characteristics and tumor recurrences, using the Mann-Whitney U test and chi-squared test.</p><p><strong>Results: </strong>Of the 100 patients, 14 had TR (14%); this occurred in tumors with higher RENAL nephrometry scores (P = 0.028) and mostly with papillary renal cell carcinomas (P = 0.043). Median warm ischemia time was longer for the TR group (22 <i>vs.</i> 15 min, <i>P</i> = 0.026). In terms of studied outcomes, there were no cases of local or distant recurrence after a median observation time of 39 months (interquartile range, 31-47 months) in both groups. We observed positive surgical margins on the final oncologic report in one case in the no-TR group.</p><p><strong>Conclusions: </strong>Tumor rupture during RAPN seems to be of no mid-term oncologic importance. According to presented results, we would recommend surgeons to proceed with tumor resection if this event occurs and abstain from conversion to radical nephrectomy or open partial nephrectomy. However, more similar cases should be studied to make more solid conclusions.</p>\",\"PeriodicalId\":21034,\"journal\":{\"name\":\"Radiology and Oncology\",\"volume\":\"57 3\",\"pages\":\"348-355\"},\"PeriodicalIF\":2.1000,\"publicationDate\":\"2023-07-20\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10476903/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Radiology and Oncology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.2478/raon-2023-0031\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2023/9/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q3\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Radiology and Oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2478/raon-2023-0031","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/9/1 0:00:00","PubModel":"eCollection","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0
摘要
背景:在日常临床实践中,机器人辅助部分肾切除术(RAPN)中可能发生术中肾肿瘤破裂(TR),但对于其处理和影响尚无可靠的指南。本研究的目的是探讨TR对肿瘤复发的影响,如果发生这种不良事件,外科医生应该怎么做,以及如何避免它。患者和方法:我们回顾性分析了2018年至2021年间在卢布尔雅那大学医学中心接受RAPN治疗的前100名患者。根据患者、肿瘤、病理、围手术期及术后特征及肿瘤复发情况,将患者分为TR组和未TR组,采用Mann-Whitney U检验和卡方检验进行比较。结果:100例患者中,14例发生TR (14%);这种情况发生在肾肾测量评分较高的肿瘤中(P = 0.028),主要发生在乳头状肾细胞癌(P = 0.043)。TR组中位热缺血时间更长(22 min vs. 15 min, P = 0.026)。在研究结果方面,两组患者在中位观察时间39个月(四分位数范围31-47个月)后均无局部或远处复发病例。我们在无tr组中观察到一例最终肿瘤报告的阳性手术切缘。结论:RAPN期间的肿瘤破裂似乎没有中期肿瘤学意义。根据目前的研究结果,我们建议外科医生进行肿瘤切除术,如果发生这种情况,避免转行根治性肾切除术或开放式部分肾切除术。然而,应该研究更多类似的案例,以得出更可靠的结论。
Does tumor rupture during robot-assisted partial nephrectomy have an impact on mid-term tumor recurrences?
Background: Intraoperative kidney tumor rupture (TR) can occur during robot-assisted partial nephrectomy (RAPN) in daily clinical practice, but there are no solid guidelines on the management and implications of it. The purpose of the study was to investigate the impact of TR on tumor recurrences, what a surgeon should do if this adverse event occurs, and how to avoid it.
Patients and methods: We retrospectively analyzed the first 100 patients who underwent RAPN at University Medical Centre Ljubljana, between 2018 and 2021. Patients were stratified into 2 groups (TR and no-TR) and were compared according to patient, tumor, pathologic, perioperative and postoperative characteristics and tumor recurrences, using the Mann-Whitney U test and chi-squared test.
Results: Of the 100 patients, 14 had TR (14%); this occurred in tumors with higher RENAL nephrometry scores (P = 0.028) and mostly with papillary renal cell carcinomas (P = 0.043). Median warm ischemia time was longer for the TR group (22 vs. 15 min, P = 0.026). In terms of studied outcomes, there were no cases of local or distant recurrence after a median observation time of 39 months (interquartile range, 31-47 months) in both groups. We observed positive surgical margins on the final oncologic report in one case in the no-TR group.
Conclusions: Tumor rupture during RAPN seems to be of no mid-term oncologic importance. According to presented results, we would recommend surgeons to proceed with tumor resection if this event occurs and abstain from conversion to radical nephrectomy or open partial nephrectomy. However, more similar cases should be studied to make more solid conclusions.
期刊介绍:
Radiology and Oncology is a multidisciplinary journal devoted to the publishing original and high quality scientific papers and review articles, pertinent to diagnostic and interventional radiology, computerized tomography, magnetic resonance, ultrasound, nuclear medicine, radiotherapy, clinical and experimental oncology, radiobiology, medical physics and radiation protection. Therefore, the scope of the journal is to cover beside radiology the diagnostic and therapeutic aspects in oncology, which distinguishes it from other journals in the field.